ABC | Volume 111, Nº5, November 2018

Original Article Rattanawong et al PR interval and chronic resynchronization therapy Arq Bras Cardiol. 2018; 111(5):710-719 Figure 2 – Forest plot of the included studies assessing the association between prolonged PR and risk of all-cause mortality (2A), HF hospitalization (2B), and composite outcome (2C). 1.12 (1.02, 1.22) 42.35 19.02 1.48 (1.01, 2.17) 1.67 (1.14, 2.44) 19.38 19.25 1.45 (0.99, 2.12) 1.34 (1.08, 1.67) 100.00 1.28 (1.18, 1.39) 1.60 (1.06, 2.43) 1.30 (1.16, 1.45) 1.23 (1.13, 1.33) 1.20 (0.78, 1.85) 1.14 (0.97, 1.34) 1.34 (1.01, 1.77) 1.21 (1.13, 1.30) 93.32 6.68 100.00 72.90 2.54 18.52 6.04 100.00 Freidman et al, 2016 Januszkiewicz et al, 2015 Kronborg et al, 2010 Lee et al, 2014 Overall (l-squared = 57.0%, p = 0.072) Heterogeneity chi-squared = 6.98 (d.f. = 3) Estimate of between-study variance Tau-squared = 0.0277 Test of overall effect: z = 2.62 (p = 0.009) Freidman et al, 2016 Januszkiewicz et al, 2015 Overall (l-squared = 6.6%, p = 0.301) Heterogeneity chi-squared = 1.07 (d.f. = 1) Estimate of between-study variance Tau-squared = 0.0016 Test of overall effect: z = 4.67 (p = 0.000) Freidman et al, 2016 Januszkiewicz et al, 2015 Olshansky et al, 2012 Rickard et al, 2017 Overall (l-squared = 0.0%, p = 0.773) Heterogeneity chi-squared = 1.12 (d.f. = 3) Estimate of between-study variance Tau-squared = 0.000 Test of overall effect: z = 5.53 (p = 0.000) .1 1 10 Favors normal PR Favors prolonged PR .1 1 10 Favors normal PR Favors prolonged PR .1 1 10 Favors normal PR Favors prolonged PR A) All-cause mortality B) Heart failure hospitalization C) Composite outcome Study, Year Risk Ratio (95% Cl) %Weight Study, Year Risk Ratio (95% Cl) %Weight Study, Year Risk Ratio (95% Cl) %Weight 715